Have a personal or library account? Click to login
Fingolimod exerts in vitro anticancer activity against hepatocellular carcinoma cell lines via YAP/TAZ suppression Cover

Fingolimod exerts in vitro anticancer activity against hepatocellular carcinoma cell lines via YAP/TAZ suppression

Acta Pharmaceutica
Volume 72 (2022): Issue 3 (September 2022)
By: Jiamin Du,  Meijia Qian,  Tao Yuan,  Bo Zhang,  Xueqin Chen,  Ning An,  Qiaojun He,  Bo Yang,  Song Ye and  Hong Zhu  
Open Access
|Apr 2022

Download Article

Download the full article as a PDF file.

DOI: https://doi.org/10.2478/acph-2022-0029 | Journal eISSN: 1846-9558 | Journal ISSN: 1330-0075
Journal RSS Feed
Language: English
Page range: 427 - 436
Accepted on: Jan 19, 2022
Published on: Apr 13, 2022
Published by: Croatian Pharmaceutical Society
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
fingolimod,
hepatocellular carcinoma,
hippo signalling,
YAP/TAZ
Related subjects:
Pharmacy,
Pharmacy, other

© 2022 Jiamin Du, Meijia Qian, Tao Yuan, Bo Zhang, Xueqin Chen, Ning An, Qiaojun He, Bo Yang, Song Ye, Hong Zhu, published by Croatian Pharmaceutical Society
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Previous articleVolume 72 (2022): Issue 3 (September 2022)Next article